Search Orphan Drug Designations and Approvals
-
Generic Name: | Iobenguane I 123 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | AdreView | ||||||||||||||||
Date Designated: | 12/01/2006 | ||||||||||||||||
Orphan Designation: | For the diagnosis of pheochromocytomas | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
GE Healthcare, Inc. 101 Carnegie Center Princeton, New Jersey 08540 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | Iobenguane I 123 |
---|---|---|
Trade Name: | AdreView | |
Marketing Approval Date: | 09/19/2008 | |
Approved Labeled Indication: | To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests | |
Exclusivity End Date: | 09/19/2015 | |
Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-